Yttrium-90 biodistribution by yttrium-87 imaging: a theoretical feasibility analysis

Area of Science:

• Nuclear Medicine
• Radiopharmaceutical Chemistry
• Medical Imaging

Background:

• Yttrium-90 (90Y) is crucial for radioimmunotherapy but lacks imaging capabilities.
• Indium-111 (111In) is a current tracer, but advances allow higher energy imaging.
• Novel tracers are needed for effective 90Y-labeled antibody distribution monitoring.

Purpose of the Study:

• To theoretically analyze the feasibility of using Yttrium-87 (87Y) as an in vivo imaging tracer for 90Y-labeled antibodies.
• To evaluate potential contaminants (87mY, 87mSr) and their impact on 87Y's utility.
• To perform dosimetry to assess absorbed dose and potential toxicity of 87Y.

Main Methods:

• Theoretical analysis of 87Y properties, including its decay and production via the 87Sr(p,n)87Y reaction.
• Modeling of contaminant levels (87mY, 87mSr) after a 100-hour delay post-bombardment.
• Dosimetric calculations to estimate absorbed radiation dose from 87Y and its daughter products.

Main Results:

• 87Y emits photons at 485 keV with high yield, suitable for advanced gamma cameras.
• A 100-hour delay significantly reduces metastable 87Y activity, minimizing imaging interference.
• In vivo, rapid equilibration between 87Y and 87mSr is expected; 87mSr's short-range electrons and photon emissions allow for independent imaging and dosimetry.

Conclusions:

• 87Y is theoretically feasible as an in vivo imaging tracer for 90Y-labeled antibodies.
• Contaminant levels can be managed with target delays, and 87mSr's emissions allow for toxicity assessment.
• 87Y warrants further investigation as a valuable imaging agent in radioimmunotherapy.